Mupirocin PCD Pharma Franchise Company
Cafoli Lifecare offers 2 Mupirocin formulations in cream and ointment form for the dermatology and wound-care segment. Both are manufactured at WHO-GMP certified facilities and offered to franchise partners on a monopoly basis.
What is Mupirocin?
Mupirocin is a topical antibacterial that inhibits bacterial isoleucyl-tRNA synthetase, halting protein synthesis. Its mechanism is distinct from other antibiotic classes, so cross-resistance is uncommon, and it is active against staphylococci including MRSA. Further detail is available on MedlinePlus.
Therapeutic Applications
Mupirocin is used for impetigo, folliculitis, infected minor wounds, cuts and abrasions, secondarily infected dermatoses and nasal decolonisation of Staphylococcus aureus. Prescribers include dermatologists, general physicians, paediatricians and surgeons.
Why Mupirocin is a High-Potential Molecule for Distributors
Unlike commodity topical antibiotics, Mupirocin holds a defensible clinical niche: it works where resistance has undermined older agents, and it is the preferred choice for impetigo and MRSA decolonisation. It therefore commands better realisations, and it pairs naturally with an existing derma or surgical call list without needing a separate promotional effort.
Why Choose Cafoli Lifecare
Cafoli provides district-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, competitive net rates and complete promotional inputs, with 1000+ franchise partners across India.
References
- MedlinePlus: Mupirocin (topical)
- PubChem: Mupirocin
Our formulations of Mupirocin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: